Pacer Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
Pacer Advisors's RXRX Position: Q2 2026 in Review
Pacer Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 10,248 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #2104 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in RXRX as recently as Q2 2024.
Pacer Advisors first reported a position in RXRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $38K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- Pacer Advisors held 10,248 shares of Recursion Pharmaceuticals worth $38K as of Q2 2026.
- Recursion Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
- Recursion Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2104 holding.
- Pacer Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
- Pacer Advisors's Recursion Pharmaceuticals position peaked at $38K in Q1 2024.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.